SIWA Therapeutics

Siwa Therapeutics

Biotechnology, 400 E Randolph St, Chicago, Illinois, 60601, United States, 1-10 Employees

siwatherapeutics.com

  • LinkedIn

phone no Phone Number: 31********

Who is SIWA THERAPEUTICS

SIWA Therapeutics is a privately held preclinical stage biotechnology company that has a monoclonal antibody that targets and destroys senescent cells. Our current therapeutic focus is on...

Read More

map
  • 400 E Randolph St, Chicago, Illinois, 60601, United States Headquarters: 400 E Randolph St, Chicago, Illinois, 60601, United States
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $1 Million to $5 Million

industries-icon Industry: Biotechnology

SIC SIC Code: 6799 | NAICS Code: 54 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from SIWA THERAPEUTICS

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding SIWA Therapeutics

Answer: SIWA Therapeutics's headquarters are located at 400 E Randolph St, Chicago, Illinois, 60601, United States

Answer: SIWA Therapeutics's phone number is 31********

Answer: SIWA Therapeutics's official website is https://siwatherapeutics.com

Answer: SIWA Therapeutics's revenue is $1 Million to $5 Million

Answer: SIWA Therapeutics's SIC: 6799

Answer: SIWA Therapeutics's NAICS: 54

Answer: SIWA Therapeutics has 1-10 employees

Answer: SIWA Therapeutics is in Biotechnology

Answer: SIWA Therapeutics contact info: Phone number: 31******** Website: https://siwatherapeutics.com

Answer: SIWA Therapeutics is a privately held preclinical stage biotechnology company that has a monoclonal antibody that targets and destroys senescent cells. Our current therapeutic focus is on certain rare and fast track diseases, including cancer metastasis and muscle wasting diseases, such as muscular dystrophy. Beyond these indications, senescent cells are causally implicated in a wide variety of diseases including: neurodegenerative diseases; autoimmune conditions, and infectious diseases. SIWA is currently optimizing its lead antibody, SIWA 318, and in parallel, seeking partnerships to advance SIWA 318 and other related technologies to broaden and accelerate its development pipeline.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access